# Debate prop_0635__kimi-k3__grok-4.6-high__s1__tpl_placement_active_20260813a

- topic_id: prop_0635
- proposition: AI model providers should face product-liability-style responsibility for foreseeable harms caused by deployed model behavior when reasonable safeguards were not implemented.
- model_pro: kimi-k3
- model_con: grok-4.6-high
- side_swap: True

## Turn 1: PRO Opening

- model: kimi-k3
- raw_words: 323
- clipped_words: 323
- claim_ids: [P1.1], [P1.2], [P1.3], [P1.4], [P1.5]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[P1.1] When a carmaker discovers a brake defect and ships anyway, no one asks whether executives meant to hurt anyone. The company pays, because the harm was foreseeable and the product was defective. That ordinary principle built modern product safety. The question is why firms deploying models into millions of lives should be the only manufacturers excused from it.
[P1.2] This is not about punishment; it is about who carries the cost. Today providers capture the revenue while foreseeable losses land on strangers: the teenager steered toward self-harm by a chatbot no reasonable testing would have released, the shopkeeper defamed by confident falsehoods, the patient harmed by invented medical advice. When the actor best placed to prevent a harm pays nothing for it, we get more of it. That is the economics of every industry we regulate.
[P1.3] Why liability rather than regulators or ordinary lawsuits? Because only the provider can see inside the model: it runs the evaluations, chooses the deployment settings, and learns of failure modes first. A victim cannot subpoena tests that were never run; a regulator cannot write rules faster than the technology changes. Product liability exists precisely for complex products whose defects buyers cannot inspect — it puts the duty on the one actor with the knowledge and the leverage.
[P1.4] And notice what the motion actually demands: foreseeable harm, and safeguards that were reasonable but absent. That double filter spares the unpredictable edge case and the novel misuse. It catches only the known risk left unguarded — the model shipped without the guardrails its own engineers would have flagged.
[P1.5] We will hear that liability chills innovation. It chills recklessness: crash standards did not end the automobile; they made it a trusted industry, and firms taking reasonable precautions win under this standard. The clash is simple — when a deployed model predictably hurts someone because its maker skipped the safeguards, who pays: the company that shipped it, or the stranger it hurt?

## Turn 2: CON Opening

- model: grok-4.6-high
- raw_words: 274
- clipped_words: 274
- claim_ids: [C1.1], [C1.2], [C1.3], [C1.4], [C1.5]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[C1.1] Product liability fits a cracked axle. It does not fit a general-purpose model whose every output is jointly produced by a prompt, a wrapper, a user, and a context the manufacturer never sees. Treating that system as a defective brake is the category error this motion depends on.
[C1.2] A car has one intended use and a finite set of failure modes. A deployed model has millions of uses, many created after release by people the provider never contracted with. “Foreseeable harm” then covers almost everything: medical questions, jailbreaks, defamatory reuse. After the fact, every tragedy looks like a skipped safeguard. That is not a duty of care; it is strict liability dressed in reasonableness language.
[C1.3] The motion also names the wrong payer. The actor best placed to prevent harm is often not the model provider. A hospital that wires a chatbot into discharge instructions, an app that strips refusals for engagement, a user who ignores warnings—those choices convert a tool into a hazard. Upstream product liability makes the least informed party the insurer of every downstream decision.
[C1.4] The advertised filter will not stay narrow. Once courts may ask whether one more eval, refusal, or withheld capability would have been “reasonable,” providers will ship less, open-source less, and avoid high-stakes domains. Large incumbents can litigate; smaller labs cannot. Safety theater plus concentration is not the automobile story.
[C1.5] Victims already have negligence, defamation, consumer protection, and contract—doctrines that ask who actually caused the injury. This motion replaces that inquiry with a manufacturer tax on language. A company that ships a capable model should not carry the loss for every foreseeable misuse someone else chose to enable.

## Turn 3: PRO Rebuttal 1

- model: kimi-k3
- raw_words: 334
- clipped_words: 334
- claim_ids: [P2.1], [P2.2], [P2.3], [P2.4], [P2.5], [P2.6], [P2.7]
- cited_claim_ids: [C1.1], [C1.3], [C1.2], [C1.5], [C1.4]
- missing_claim_id_refs: (none)

[P2.1] The reply rests on one move: because others help shape the output, the provider owes nothing [C1.1]. But joint causation is not a defense in product law — it is the normal case. A drug's effect depends on prescriber, pharmacist, and patient; the manufacturer still answers for a defective design or a missing warning. Comparative fault apportions the hospital's share and the user's; it does not erase the maker's.
[P2.2] The motion says responsibility, not a monopoly on blame.
[P2.3] That also answers the "wrong payer" argument. CON calls the provider "the least informed party" [C1.3] — backwards. The provider trains the model, runs the evals, sets the refusals, and sees failure reports first. The hospital wiring a chatbot into discharge instructions cannot inspect the weights; it relies on what the provider tested and disclosed.
[P2.4] The duty tracks information, which is exactly where the motion puts it.
[P2.5] On foreseeability swallowing everything [C1.2]: courts judge it ex ante — what the provider knew or should have known at deployment, from its own red-team results, incident history, and documented misuse patterns. Design-defect law runs this risk-utility analysis daily for drugs and aircraft without becoming strict liability. Hindsight cannot invent knowledge the provider lacked; it easily proves the risk flagged in the company's own testing and shipped anyway.
[P2.6] Notice the tension: CON warns the standard covers everything, then insists existing doctrines already protect victims [C1.5]. Negligence fails when the decisive tests were never run and cannot be discovered; defamation and contract abandon the teenager and the defamed shopkeeper — no privity, no speaker to sue. The gap is real, and it is precisely what the double filter fills.
[P2.7] Finally, the chilling story [C1.4]. What gets chilled is deploying a medical chatbot without reasonable safeguards — which is the point. Reasonableness scales to firm size and documented effort; it rewards real testing, not theater. CON defends a world where the company that saw the risk, skipped the guardrail, and kept the revenue pays nothing — and the stranger pays everything.

## Turn 4: CON Rebuttal 1

- model: grok-4.6-high
- raw_words: 323
- clipped_words: 323
- claim_ids: [C2.1], [C2.2], [C2.3], [C2.4], [C2.5], [C2.6], [C2.7], [C2.8]
- cited_claim_ids: [P2.4], [P2.5], [P2.7]
- missing_claim_id_refs: (none)

[C2.1] The drug analogy fails at the first step. A manufacturer answers for defective design because the product has an intended use, a label, and finite indications against which defect is measured. A general-purpose model has none of those. Calling a skipped refusal a "design defect" is how every downstream use becomes the manufacturer's problem.
[C2.2] Comparative fault can split a known defect; it cannot define one when the alleged flaw is that language can be used badly.
[C2.3] "Duty tracks information" [P2.4] is the wrong test. The provider trains the model; the hospital still wires it into discharge instructions; the app still strips refusals. Seeing evals does not make you the cheapest avoider of someone else's deployment. Information without control is not a reason to make the upstream party the insurer.
[C2.4] "Ex ante from red-team results" [P2.5] sounds disciplined until you notice what red-teaming a general model surfaces on day one: medical questions, self-harm talk, defamation, jailbreaks. Under this motion those patterns are all foreseeable, so the only live question is whether one more safeguard was "reasonable." After injury, that answer is always yes. Strict liability with extra steps.
[C2.5] The gap in existing law is overstated. If a company saw a failure and shipped anyway, negligence already reaches that conduct, including discovery of what was known. Defamation still reaches the speaker who republishes. This motion is offered because ordinary proof is hard.
[C2.6] Hard is not a hole that requires shifting every residual loss onto the model maker.
[C2.7] Reasonableness will not "scale to firm size" [P2.7] before a jury looking at a harmed teenager. Large incumbents absorb that risk; smaller labs and open releases do not. What gets chilled is not only the reckless medical bot. It is the capable general model anyone else can wire into a high-stakes setting.
[C2.8] The motion does not punish recklessness. It taxes capability — and hands the cost of every later choice back to the party that never made it.

## Turn 5: PRO Pressure Questions

- model: kimi-k3
- raw_words: 94
- clipped_words: 94
- claim_ids: [P3.1], [P3.2]
- cited_claim_ids: [C2.5], [C2.4]
- missing_claim_id_refs: (none)

[P3.1] Q1: You claim existing doctrines already reach this conduct [C2.5]. For the teenager steered toward self-harm, name the defendant and the duty: defamation needs a republisher, contract needs privity, and negligence cannot discover tests that were never run. Who pays, and on what theory?
[P3.2] Q2: You call the reasonable-safeguard inquiry "strict liability with extra steps" [C2.4]. Then say it plainly: is there any case — a red-team flag documented and ignored at launch — where you would hold the provider liable? If yes, you have conceded the motion. If no, you are defending immunity.

## Turn 6: CON Pressure Questions

- model: grok-4.6-high
- raw_words: 65
- clipped_words: 65
- claim_ids: [C3.1], [C3.2]
- cited_claim_ids: [P2.1], [P1.4]
- missing_claim_id_refs: (none)

[C3.1] Q1: Under the drug analogy [P2.1], what intended use measures a model's defect? If every possible prompt counts, how does your double filter [P1.4] not treat every known dual-use as a skipped safeguard?
[C3.2] Q2: If a hospital ignores a clinical-use warning and strips refusals, does the provider still pay under this motion? Yes names the wrong cheapest avoider; no, your teenager and shopkeeper cases collapse.

## Turn 7: PRO Rebuttal 2

- model: kimi-k3
- raw_words: 321
- clipped_words: 321
- claim_ids: [P4.1], [P4.2], [P4.3], [P4.4], [P4.5]
- cited_claim_ids: [C3.1], [C3.2], [P3.1], [P3.2]
- missing_claim_id_refs: (none)

[P4.1] A1: No single intended use is required — product law has never demanded one [C3.1]. Chainsaws, ladders, and drugs are judged against foreseeable uses and foreseeable misuse through risk-utility analysis: was the risk known, and was a feasible precaution skipped? A general-purpose model is broader, not different in kind. And the double filter does the narrowing: foreseeability runs from what the provider's own red-teaming and incident history documented at deployment, while "reasonable" means an available, proportionate safeguard — not omniscience.
[P4.2] Dual-use capability is not a defect; shipping with a documented risk and a skipped guardrail is. Not every prompt counts — only the ones the provider's own evidence says it saw coming.
[P4.3] A2: No — and the teenager's case stands, because the standard is comparative, not binary [C3.2]. A provider that warned against clinical use and built reasonable refusals has discharged its duty; comparative fault then lays the loss on the hospital that stripped them. The teenager's case involves no professional overriding warnings — the harm flows from the model's own unguarded behavior. Their fork — wrong avoider or collapsed cases — dissolves once blame can be shared, as product law does daily.
[P4.4] Now notice the asymmetry. Both of their questions are answered; mine [P3.1], [P3.2] are not. No defendant has been named for the teenager under existing law, and no one has taken the fork: is there any documented-flag case where the provider pays? Dodging the first concedes the gap is real; dodging the second concedes their position is immunity, not a better standard.
[P4.5] That leaves one surviving claim: juries cannot run this reasonableness inquiry. Yet courts run it daily for drugs, aircraft, and medical devices — products whose failure modes also depend on users and intermediaries. Their chill argument is a forecast; the uncompensated victim is a fact. The opening question still stands: when the maker saw the risk, skipped the safeguard, and kept the revenue — who pays?

## Turn 8: CON Rebuttal 2

- model: grok-4.6-high
- raw_words: 318
- clipped_words: 318
- claim_ids: [C4.1], [C4.2], [C4.3], [C4.4], [C4.5], [C4.6], [C4.7]
- cited_claim_ids: [P3.1], [P1.4], [P4.1], [P4.3]
- missing_claim_id_refs: (none)

[C4.1] A1: The provider, in negligence, when its records show it knew a specific self-harm pathway and failed ordinary care. Discovery reaches those records. Claiming "tests that were never run" cannot be found [P3.1] treats missing paperwork as a defect. If the path was not reasonably knowable, existing law leaves the loss unshifted — as would the motion's edge-case filter [P1.4].
[C4.2] Defamation and contract are not the only remaining theories.
[C4.3] A2: Yes — under negligence, for ignoring a documented, specific, preventable risk. That is not this motion. The motion is product-liability-style responsibility for deployed model behavior whenever a later jury thinks one more safeguard was "reasonable." Liability for reckless disregard does not concede that every general model is a defective product.
[C4.4] The fork is false: reject the doctrine without granting immunity. Those answers leave their case as a category error dressed as a gap-filler. They admit no intended use measures the defect [P4.1], only "foreseeable uses" drawn from day-one red-team patterns. That is how medical talk, jailbreaks, and defamation all become skipped guardrails.
[C4.5] Comparative fault cannot save a standard that must first call the output defective. Sharing blame assumes a defect; it does not define one. Their hospital answer [P4.3] proves the bind. If warnings plus refusals discharge the duty, this motion is negligence with a product-law label.
[C4.6] If they do not — if a later wrapper or a teenager's prompt still counts as the model's "unguarded behavior" — the provider remains insurer of choices it never made. They need the second result for the uncompensated victim and the first to deny a chill. They cannot have both. Courts can run risk-utility on a saw or a pill because the product has a job.
[C4.7] A general model's job is language. Taxing that job for every documented dual-use does not close a hole in tort. It dumps residual loss on the party that never wired the tool into a life.

## Turn 9: PRO Closing

- model: kimi-k3
- raw_words: 207
- clipped_words: 207
- claim_ids: [P5.1], [P5.2], [P5.3], [P5.4]
- cited_claim_ids: [C4.3], [C4.5]
- missing_claim_id_refs: (none)

[P5.1] Look where this debate ends. Faced with the fork, CON answered: yes, a provider that ignores a documented, specific risk should pay [C4.3]. That is the motion's whole content — foreseeable harm, a reasonable safeguard skipped, responsibility follows. What remains is a quarrel over the label.
[P5.2] But the label is the substance. What CON dismisses as "negligence with a product-law label" [C4.5] means the duty runs to everyone foreseeably harmed — no privity, no republisher required — and centers on the maker's own testing rather than evidence victims cannot reach. That is the difference between a duty on paper and one a teenager's family can enforce.
[P5.3] The final bind dissolves too. A defect is a documented risk plus a skipped, feasible precaution; warnings and real refusals discharge it because the duty tracks what the provider controlled, while comparative fault prices the hospital's choices. That is not contradiction — it is product law working as designed.
[P5.4] So it comes to this: CON concedes the reckless maker should pay, yet offers victims only theories needing a contract, a speaker, or tests that were never run. The motion closes that gap. The maker saw the risk, skipped the guardrail, kept the revenue. It should not be the stranger who pays.

## Turn 10: CON Closing

- model: grok-4.6-high
- raw_words: 183
- clipped_words: 183
- claim_ids: [C5.1], [C5.2], [C5.3], [C5.4], [C5.5], [C5.6]
- cited_claim_ids: [P5.1]
- missing_claim_id_refs: (none)

[C5.1] They call our concession the motion [P5.1]. It is not. Liability for reckless disregard was never the issue. Treating every general model as a defective product is.
[C5.2] A maker who ignores a documented, specific risk can already lose in negligence. This motion is product-liability-style responsibility for deployed model behavior: a later jury deciding one more safeguard was "reasonable."
[C5.3] That is the decision. A saw has a job. A pill has indications. A general model has language.
[C5.4] Once defect is a day-one red-team pattern plus a skipped refusal, the double filter vanishes and every dual-use becomes the manufacturer's problem. Comparative fault can split a defect. It cannot invent one.
[C5.5] They need the teenager to recover without privity, which requires treating unguarded language as the product. They also need warnings to discharge the duty, or the hospital still dumps loss upstream. Those two results cannot coexist under this standard.
[C5.6] Recklessness already has a home. What they ask is that the party who never wired the tool into a life carry the residual cost of every later choice. That taxes capability, not fault. Refuse the motion.
